A Splendid Gift from the Earth: The Origins and Impact of the Avermectins (Nobel Lecture)

Angewandte Chemie - International Edition

Volumn 55, Issue 35, 2016, Pages 10190-10209

  Ōmura, Satoshi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

anthelmintics; ivermectin; medicinal chemistry; river blindness; worm infestation

Indexed keywords

EID: 84978708820     PISSN: 14337851     EISSN: 15213773     Source Type: Journal    
DOI: 10.1002/anie.201602164     Document Type: Review

References (146)

1. “Mass treatment with ivermectin: an underutilized public health strategy”: R. Speare, D. Durrheim, Bull. W. H. O. 2004, 82, 559–636.
2. “An introduction to the avermectins”: W. C. Campbell, N. Z. Vet. J. 1981, 29, 174–178.
3. “Insecticidal activity of the parasitic avermectins”: D. A. Ostlind, S. Cifelli, R. Lang, Vet. Rec. 1979, 105, 168.
4. “Avermectins: novel insecticides, acaricides and nematicides from a soil microorganism”: I. Putter, J. G. MacConnell, F. A. Preiser, A. A. Haidri, S. S. Ristich, R. A. Dybas, Experientia 1981, 37, 963–964.
5. “Computational improvements reveal great bacterial diversity and high metal toxicity in soil”: J. Gans, M. Wolinsky, J. Dunbar, Science 2005, 309, 1387–1390.
6. “Avermectins, antiparasitic lactones produced by Streptomyces avermitilis isolated from a soil in Japan”: E. O. Stapley, H. B. Woodruff, in Trends in Antibiotic research: Genetics, biosyntheses, actions & new substances (Eds.: H. Umezawa, A. L. Demain, T. Hata, C. R. Hutchinson), JARA, 1982, pp. 154–170.
7. “Spoxazomicins A–C, novel antitrypanosomal alkaloids produced by an endophytic actinomycete, Streptosporangium oxazolinicum K07-0460T”: Y. Inahashi, M. Iwatsuki, A. Ishiyama, M. Namatame, A. Nishihara-Tsukashima, A. Matsumoto, T. Hirose, T. Sunazuka, H. Yamada, K. Otoguro, Y. Takahashi, S. Ōmura, K. Shiomi, J. Antibiot. 2011, 64, 303–307.
8. “Trehangelins A, B and C, novel photo-oxidative hemolysis inhibitors produced by an endophytic actinomycete, Polymorphospora rubra K07-0510”: T. Nakashima, R. Okuyama, Y. Kamiya, A. Matsumoto, M. Iwatsuki, Y. Inahashi, K. Yamaji, Y. Takahashi, S. Ōmura, J. Antibiot. 2013, 66, 311–317.
9. “Pyrindicin, a new alkaloid from a Streptomyces strain. Taxonomy, fermentation, isolation and biological activity”: S. Ōmura, H. Tanaka, J. Awaya, Y. Narimatsu, Y. Konda, T. Hata, Agric. Biol. Chem. 1974, 38, 899–906.
10. “A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization”: S. Ōmura, Y. Iwai, A. Hirano, A. Nakagawa, J. Awaya, H. Tsuchya, Y. Takahashi, R. Masuma, J. Antibiot. 1977, 30, 275–282.
11. “Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine”: H. Nakano, S. Ōmura, J. Antibiot. 2009, 62, 17–26.
12. “Phosphorylation of Activation Transcription Factor-2 at serine 121 by protein kinase C controls c-Jun-mediated activation of transcription”: T. Yamasaki, A. Takahashi, J. Pan, N. Yamaguchi, K. K. Yokoyama, J. Biol. Chem. 2009, 284, 8567–8581.
13. “A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase”: S. Atwell, J. M. Adams, J. Badger, M. D. Buchanan, I. K. Feil, K. J. Froning, X. Gao, J. Hendle, K. Keegan, B. C. Leon, H. J. Müller-Dieckmann, V. L. Nienaber, B. W. Noland, K. Post, K. R. Rajashankar, A. Ramos, M. Russell, S. K. Burley, S. G. Buchanan, J. Biol. Chem. 2004, 279, 55827–55832.
14. “Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells”: S. Ōmura, T. Fujimoto, K. Otoguro, K. Matsuzaki, R. Moriguchi, H. Tanaka, Y. Sasaki, J. Antibiot. 1991, 44, 113–116.
15. “Structure of prumycin”: S. Ōmura, M. Katagiri, K. Atsumi, T. Hata, A. A. Jakubowski, E. Bleecker-Springs, M. Tishler, J. Chem. Soc. Perkin Trans. 1 1974, 1627–1631.
16. “Relationships of structure and microbiological activities of the 16-membered macrolides”: S. Ōmura, M. Tishler, A. Nakagawa, Y. Hironaka, T. Hata, J. Med. Chem. 1972, 15, 1011–1015.
17. “A new antifungal antibiotic, prumycin”: T. Hata, S. Ōmura, M. Katagiri, K. Atsumi, J. Awaya, J. Antibiot. 1971, 24, 900–901.
18. “Studies on cerulenin. III. Isolation and physico-chemical properties of cerulenin”: Y. Sano, S. Nomura, Y. Kamio, S. Ōmura, T. Hata, J. Antibiot. 1967, 20, 344–348.
19. “Structure-biological activities relationships among leucomycins and their derivatives”: S. Ōmura, M. Katagiri, I. Umezawa, K. Komiyama, T. Maekawa, K. Sekikawa, A. Matsumae, T. Hata, J. Antibiot. 1968, 21, 532–538.
20. “Luminamicin, a new antibiotic. Production, isolation and physico-chemical and biological properties”: S. Ōmura, R. Iwata, Y. Iwai, S. Taga, Y. Tanaka, H. Tomoda, J. Antibiot. 1985, 38, 1322–1326.
21. “New antitumor antibiotics, OS-4742 A1, A2, B1 and B2 produced by a strain of Streptomyces”: S. Ōmura, H. Tanaka, R. Oiwa, J. Awaya, R. Masuma, K. Tanaka, J. Antibiot. 1977, 30, 908–916.
22. “Setamycin, a new antibiotic”: S. Ōmura, K. Otoguro, T. Nishikiori, R. Oiwa, Y. Iwai, J. Antibiot. 1981, 34, 1253–1256.
23. “Structure of elasnin, a novel elastase inhibitor”: S. Ōmura, A. Nakagawa, H. Ohno, J. Am. Chem. Soc. 1979, 101, 4386–4388.
24. “Factumycin, a new antibiotic (A40A): fermentation, isolation and antibacterial spectrum”: V. P. Gullo, S. B. Zimmerman, R. S. Dewey, O. Hensens, P. J. Cassidy, R. Oiwa, S. Ōmura, J. Antibiot. 1982, 35, 1705–1707.
25. “Max Tishler”: L. H. Sarrett, C. Roche, in Biographical memoirs, Vol. 66, National Academies Press, 1995, pp. 352–369.
26. “Avermectins and related compounds: In Natural Products Isolation: Separation Methods for Antimicrobials”: T. W. Miller, V. P. Gullo, Journal of Chromatography Library, Vol. 43 (Eds.: G. H. Wagman, R. Cooper), Elsevier, Amsterdam, 1989, pp. 347–376.
27. “Ivermectin: a potent new antiparasitic agent”: W. C. Campbell, M. H. Fisher, E. O. Stapley, G. Albers-Schonberg, T. A. Jacob, Science 1983, 221, 823–828.
28. “Streptomyces avermectinius sp. nov., an avermectin-producing strain”: Y. Takahashi, A. Matsumoto, A. Seino, J. Ueno, Y. Iwai, S. Ōmura, Int. J. Syst. Evol. Microbiol. 2002, 52, 2163–2168.
29. “Avermectins: Structure determination”: G. Albers-Schönberg, B. H. Arison, J. C. Chabala, A. W. Douglas, P. Eskola, M. H. Fisher, A. Lusi, H. Mrozik, J. L. Smith, R. L. Tolman, J. Am. Chem. Soc. 1981, 103, 4216–4221.
30. “Avermectins, new family of potent anthelmintic agents: producing organisms and fermentation”: R. W. Burg, B. M. Miller, E. E. Baker, J. Birnbaum, S. A. Currie, R. Hartman, Y. L. Kong, R. L. Monaghan, G. Olson, I. Putter, J. B. Tunac, H. Wallick, E. O. Stapley, R. Oiwa, S. Ōmura, Antimicrob. Agents Chemother. 1979, 15, 361–367.
31. “Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties”: T. W. Miller, L. Chaiet, D. J. Cole, L. J. Cole, J. E. Flor, R. T. Goegleman, V. P. Gullo, H. Joshua, A. J. Kempf, W. R. Krellwitz, R. L. Monaghan, R. E. Ormond, K. E. Wilson, G. Albers-Schönberg, I. Putter, Antimicrob. Agents Chemother. 1979, 15, 368–371.
32. “Avermectins, new family of potent anthelmintic agents: efficacy of the B1A component”: J. R. Egerton, D. A. Ostlind, L. S. Blair, C. H. Eary, D. Suhayda, S. Cifelli, R. F. Riek, W. Campbell, Antimicrob. Agents Chemother. 1979, 15, 372–378.
33. “Ivermectin, a new broad-spectrum antiparasitic agent”: J. C. Chabala, H. Mrozik, R. L. Tolman, P. Eskola, A. Lusi, L. H. Peterson, M. F. Woods, M. H. Fisher, W. C. Campbell, J. Med. Chem. 1980, 23, 1134–1136.
34. “Efficacy of the avermectins against filarial parasites: a short review”: W. C. Campbell, Vet. Res. Commun. 1981, 5, 251–262.
35. “The avermectins: A new family of antiparasitic agents”: I. K. Hotson, J. South African Vet. Assoc. 1982, 53, 87–90.
36. “Investigations of the efficacy of ivermectin against ectoparasites in cattle”: D. Barth, I. H. Sutherland, Zentral. Bakt. Parasit. Infect. Hyg. 1980, 57, 319.
37. “On the efficacy of ivermectin versus ticks (O. moubata, R. appendiculatus, A. variegatum) in cattle”: C. Centurier, D. Barth, Zentral. Bakt. Parasit. Infect. Hyg. 1980, 58, 319–320.
38. Ivermectin and Abamectin (Ed.: W. C. Campbell), Springer, New York, 1989.
39. “A partnership for ivermectin: Social worlds and boundary objects”: L. Frost, M. R. Reich, T. Fujisaki, in Public-Private: Partnerships for Global Health (Ed.: M. R. Reich), Harvard University Press, 2002, pp. 87–114.
40. S. Ōmura, Macrolide Antibiotics. Chemistry, Biology and Practice, 2nd edn (Ed.: S. Ōmura) Academic Press, San Diego, 2002, pp. 571–576.
41. “Actions of dihydroavermectin B1a on insect muscle”: R. Duce, R. H. Scott, Br. J. Pharmacol. 1985, 85, 395–401.
42. “Haemonchus contortus: ivermectin induced paralysis of the pharynx”: T. G. Geary, S. M. Sims, E. M. Thomas, L. Vanover, J. P. Davis, C. A. Winterrowd, R. D. Klein, H. F. Ho, D. P. Thompson, Exp. Parasitol. 1993, 77, 88–96.
43. “Avermectin B1a irreversibly blocks postsynaptic potentials at the lobster neuromuscular junction by reducing muscle membrane resistance”: L. C. Fritz, C. C. Wang, A. Gorio, Proc. Natl Acad. Sci. USA 1979, 76, 2062–2066.
44. “Post-synaptic inhibition of invertebrate neuromuscular transmission by avermectin B1a”: T. N. Mellin, R. D. Busch, C. C. Wang, Neuropharmacology 1983, 22, 89–96.
45. M. Turner, J. M. Schaeffer, in Ivermectin and Abamectin (Ed.: W. C. Campbell), Springer, New York, 1989, pp. 73–88.
46. “Ivermectin: an update”: W. C. Campbell, Parasitol. Today 1985, 1, 10–16.
47. “Treatment of 18 children with scabies or cutaneous larva migrans using ivermectin”: M. del Mar Saez-De-Ocariz, C. D. McKinster, L. Orozco-Covarrubias, L. Tamayo-Sánchez, R. Ruiz-Maldonaldo, Clin. Exp. Dermatol. 2002, 27, 264–267.
48. “Immunological tolerance: the key feature in human filariasis?”: R. M. Maizels, R. A. Lawrence, Parasitol. Today 1991, 7, 271–276.
49. “The status of ivermectin in the treatment of human onchocerciasis”: H. R. Taylor, B. M. Greene, Am. J. Trop. Med. Hyg. 1989, 41, 460–466.
50. “Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa”: A. P. Plaisier, E. S. Alley, B. A. Boatin, G. J. Van Oortmarssen, H. Remme, S. J. De Vlas, L. Bonneux, J. D. Habbema, J. Infect. Dis. 1995, 172, 204–210.
51. “Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis”: M.-G. Basáñez, S. D. Pion, E. Boakes, J. A. Filipe, T. S. Churcher, M. Boussinesq, Lancet Infect. Dis. 2008, 8, 310–322.
52. “Migration and death of skin-dwelling Onchocerca volvulus microfilariae after treatment with ivermectin”: B. O. Duke, G. Soula, G. Zea-Flores, G. L. Bratthauer, O. Doumbo, Trop. Med. Parasitol. 1991, 42, 25–30.
53. “Possible pathogenic pathways in the adverse clinical events seen following ivermectin administrations in onchocerciasis patients”: C. D. Mackenzie, T. G. Geary, J. A. Gerlach, Filaria J. 2003, 2, S5.
54. “Ivermectin disrupts the function of the excretory-secretory appartus in microfilariae of Brugia malayi”: Y. Moreno, J. F. Nabhan, J. Solomon, C. D. MacKenzie, T. G. Geary, Proc. Natl. Acad. Sci. USA 2010, 107, 20120–20125.
55. “Ivermectin, ”Wonder drug“ from Japan: the human use perspective”: A. Crump, S. Ōmura, Proc. Jpn. Acad. Ser. B 2011, 87, 13–28.
56. T. Fujisaki, M. Reich, TDR′s contribution to the development of ivermectin for onchocerciasis, TDR, Geneva, (TDR/ER/RD/98.3), 1998.
57. WHO/TDR, Participation of the Pharmaceutical sector (TDR/WP/76.30), 1976.
58. “Public-Private Partnerships: Illustrative examples”: A. O. Lucas, in Public-Private Partnerships for Public Health. (Ed.: M. Reich), Harvard University Press, Cambridge, 2002, pp. 19–39.
59. “History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents”: W. C. Campbell, Curr. Pharm. Biotechnol. 2012, 13, 853–865.
60. J. L. Sturchio, The Decision to Donate Mectizan: Historical Background, Merck & Co., Inc. Rahway, New JerseyUSA, 1992 (unpublished).
61. “Efficacy and tolerance of ivermectin in human onchocerciasis”: M. A. Aziz, S. Diallo, I. M. Diop, M. Larivière, M. Porta, Lancet 1982, 2, 171–173.
62. “Treatment of human onchocerciasis with ivermectin”: J. P. Coulaud, M. Larivière, M. C. Gervais, P. Gaxotte, A. Aziz, A. M. Deluol, J. Cenac, Bull. Soc. Pathol. Exot. Ses Fil. 1983, 76, 681–688.
63. “Ocular findings in a double-blind study of ivermectin versus diethylcarbamazine versus placebo in the treatment of onchocerciasis”: K. Y. Dadzie, A. C. Bird, K. Awadzi, H. Schulz-Key, H. M. Gilles, M. A. Aziz, Br. J. Ophthalmol. 1987, 71, 78–85.
64. “Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement”: M. Larivière, M. Aziz, D. Weimann, J. Ginoux, P. Gaxotte, P. Vingtain, B. Beauvais, F. Derouin, H. Schultz-Key, D. Basset, C. Sarfati, Lancet 1985, 326, 174–177.
65. “The status of ivermectin in the treatment of human onchocerciasis”: H. R. Taylor, B. M. Greene, Am. J. Trop. Med. Hyg. 1989, 41, 460–466.
66. “The chemotherapy of onchocerciasis II: Quantification of the clinical reaction to microfilaricides”: K. Awadzi, Ann. Trop. Med. Parasitol. 1980, 74, 189–197.
67. “The chemotherapy of X. onchocerciasis An assessment of four single dose treatment regimes of MK-933 (ivermectin) in human onchocerciasis”: K. Awadzi, K. Y. Dadzie, H. Shulz-Key, D. R. Haddock, H. M. Gilles, M. A. Aziz, Ann. Trop. Med. Parasitol. 1985, 79, 63–78.
68. “Ivermectin as an antiparasitic agent for use in humans”: W. C. Campbell, Annu. Rev. Microbiol. 1991, 45, 445–474.
69. “African Programme for Onchocerciasis Control 1995–2015: model-estimated health impact and cost”: L. E. Coffeng, W. A. Stolk, H. G. Zouré, J. L. Veerman, K. B. Agblewonu, M. E. Murdoch, M. Noma, G. Fobi, J. H. Richardus, D. A. Bundy, D. Habbema, S. J. de Vlas, U. V. Amazigo, PLoS Neglected Trop. Dis. 2013, 7, e2032.
70. UNESCO World Science Report 2005, UNESCO, Paris, 2005, p. 198.
71. “Dose-ranging study of ivermectin in the treatment of Filariasis due to Wuchereria bancrofti”: S. Diallo, M. A. Aziz, O. Ndir, S. Badiane, I. B. Bah, O. Gaye, Lancet 1987, 329, 1030.
72. WHO/TDR, Tropical Disease Research: Progress 1975– 1994, WHO, Geneva, 1995, p. 95.
73. “Ivermectin for treatment of Wuchereria bancrofti filariasis: efficacy and adverse reactions”: V. Kumaraswami, E. A. Ottesen, V. Vijayasekran, JAMA J. Am. Med. Assoc. 1988, 259, 3150–3153.
74. “A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis”: E. A. Ottesen, V. Kumaraswami, V. Vijayasekran, N. Engl. J. Med. 1990, 322, 1113–1117.
75. “Comparison of high-dose ivermectin and diethylcarbamazine for activity against Bancroftian filariasis in Haiti”: F. O. Richards Jr, M. L. Eberhard, R. T. Bryan, D. F. Mcneeley, P. J. Lammie, M. B. Mcneeley, Y. Bernard, A. W. Hightower, H. C. Spencer, Am. J. Trop. Med. Hyg. 1991, 44, 3–10.
76. Mectizan Donation Program, Annual Highlights (2104) MDP, Atlanta, 2015.
77. WHO, Weekly Epidemiological Report, 90, No. 49, 2015, pp. 661–680.
78. “Ivermectin: panacea for resource-poor communities?”: S. Ōmura, A. Crump, Trends Parasitol. 2014, 30, 445–455.
79. World Health Organization, Strongyloidiasis: Key Facts, World Health Organization, Geneva, 2014.
80. “Oral ivermectin treatment in two cases of scabies: effective in crusted scabies induced by corticosteroid but ineffective in nail scabies”: N. Ohtaki, H. Taniguchi, H. Ohtomo, J. Dermatol. 2003, 30, 411–416.
81. “Treatment of scabies: newer perspectives”: K. Karthikeyan, Postgrad. Med. J. 2005, 81, 7–11.
82. “Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded trial”: D. Pilger, J. Heukelbach, A. Khakban, F. A. Oliveira, G. Fengler, H. Feldmeier, Bull. W. H. O. 2010, 88, 90–96.
83. “Epidemiology and morbidity of scabies and Pediculosis capitis in resource-poor communities in Brazil”: J. Heukelbach, T. Wilcke, B. Winter, H. Feldmeier, Br. J. Dermatol. 2005, 153, 150–156.
84. “Oral ivermectin versus malathion lotion for difficult-to-treat head lice”: O. Chosidow, B. Giraudeau, J. Cottrell, A. Izri, R. Hofmann, S. G. Mann, I. Burgess, N. Engl. J. Med. 2010, 362, 896–905.
85. “Oral ivermectin for head lice: a comparison with 0.5 % topical malathion lotion”: A. Nofal, Z. Hautkrankheiten 2010, 8, 985–988.
86. “A pilot study of the use of oral ivermectin to treat head lice in primary school students in Australia”: M. J. Currie, G. J. Reynolds, N. Glasgow, Pediatr. Dermatol. 2010, 27, 595–599.
87. “Oral ivermectin for treatment of Pediculosis capitis”: M. Ameen, R. Arenas, J. Villanueva-Reyes, J. Ruiz-Esmenjaud, D. Millar, F. Domínguez-Dueñas, A. Haddad-Angulo, M. Rodríguez-Alvarez, Pediatr. Infect. Dis. J. 2010, 29, 991–993.
88. “Topical 0.5 % ivermectin lotion for treatment of head lice”: D. M. Pariser, T. L. Meinking, M. Bell, W. G. Ryan, N. Engl. J. Med. 2012, 367, 1687–1693.
89. “A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp”: V. Y. Belizario, M. E. Amarillo, W. U. de Leon, A. E. de los Reyes, M. G. Bugayong, B. J. Macatangay, Bull. W. H. O. 2003, 81, 35–42.
90. “A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children”: H. Marti, H. J. Haji, L. Savioli, H. M. Chwaya, A. F. Mgeni, J. S. Ameir, C. Hatz, Am. J. Trop. Med. Hyg. 1996, 55, 477–481.
91. “School-based health education targeting intestinal worms—further support for integrated control”: F. A. Bieri, Y. S. Li, L. P. Yuan, Y. K. He, D. J. Gray, G. M. Williams, D. P. McManus, PLoS Neglected Trop. Dis. 2014, 8, e2621.
92. “Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm”: J. Bethony, S. Brooker, M. Albonico, S. M. Geiger, A. Loukas, D. Diemert, P. J. Hotez, Lancet 2006, 367, 1521–1532.
93. “Comparison of ivermectin and albendazole treatment for gnathostomiasis”: P. Nontasut, V. Bussaratid, S. Chullawichit, N. Charoensook, K. Visetsuk, Southeast Asian J. Trop. Med. Public Health 2000, 31, 374–377.
94. “Long-term suppression of Mansonella streptocerca microfilariae after treatment with ivermectin”: P. Fischer, E. Tukesiga, D. W. Büttner, J. Infect. Dis. 1999, 180, 1403–1405.
95. “Comparison of different anthelminthic drug regimens against Mansonella perstans filariasis”: E. R. Bregani, A. Rovellini, N. Mbaidoum, M. G. Magnini, Trans. R. Soc. Trop. Med. Hyg. 2006, 100, 458–463.
96. “Ivermectin toxicity in young mice”: B. Skopets, R. P. Wilson, J. W. Griffith, C. M. Lang, Lab. Anim. Sci. 1996, 46, 111–112.
97. “Clinical signs of ivermectin toxicity and efficacy of antigabaergic convulsants as antidotes for ivermectin poisoning in epileptic chickens”: J. S. Kim, E. C. Crichlow, Vet. Hum. Toxicol. 1995, 37, 122–126.
98. “Ivermectin toxicology in a rhesus macaque”: S. A. Iliff-Sizemore, M. R. Partlow, S. T. Kelley, Vet. Hum. Toxicol. 1990, 32, 530–532.
99. “Ivermectin toxicosis after topical administration in dog-faced fruit bats (Cynopterus brachyotis)”: J. H. DeMarco, D. J. Heard, G. J. Fleming, B. A. Lock, T. J. Scase, J. Zoo Wildl. Med. 2002, 33, 147–150.
100. “Toxicity and efficacy of ivermectin in chelonians”: J. A. Teare, M. Bush, J. Am. Vet. Med. Assoc. 1983, 183, 1195–1197.
101. “Selective mass treatment with ivermectin to control intestinal helminthiasis and parasitic skin diseases in a severely affected population”: J. Heukelbach, B. Winter, T. Wilcke, M. Muehlen, S. Albrecht, F. A. de Oliveira, L. R. Kerr-Pontes, O. Liesenfeld, H. Feldmeier, Bull. W. H. O. 2004, 82, 563–571.
102. “Efficacy of ivermectin in a patient population concomitantly infected with intestinal helminths and ectoparasites”: J. Heukelbach, T. Wilcke, B. Winter, F. A. Sales de Oliveira, R. C. Sabóia Moura, G. Harms, O. Liesenfeld, H. Feldmeier, Arzneim.-Forsch. 2004, 54, 416–421.
103. “Impact of long-term treatment with ivermectin on the prevalence and intensity of soil-transmitted helminth infections”: A. L. Moncayo, M. Vaca, L. Amorim, A. Rodriguez, S. Erazo, G. Oviedo, I. Quinzo, M. Padilla, M. Chico, R. Lovato, E. Gomez, M. L. Barreto, P. J. Cooper, PLoS Neglected Trop. Dis. 2008, 2, e293.
104. “The varied beneficial effects of ivermectin (Mectizan) treatment, as observed within onchocerciasis foci in southeastern Nigeria”: J. C. Anosike, I. N. Dozie, G. I. Ameh, C. N. Ukaga, B. E. Nwoke, C. T. Nzechukwu, O. S. Udujih, D. C. Nwosu, Ann. Trop. Med. Parasitol. 2007, 101, 593–600.
105. “Where would I be without ivermectin? Capturing the benefits of community-directed treatment with ivermectin in Africa”: J. C. Okeibunor, M. Amuyunzu-Nyamongo, N. G. Onyeneho, Y. F. Tchounkeu, C. Manianga, A. T. Kabali, S. Leak, Trop. Med. Int. Health 2011, 16, 608–621.
106. “Drug resistance in nematodes of veterinary importance: a status report”: R. M. Kaplan, Trends Parasitol. 2004, 20, 477–481.
107. “The genetics of ivermectin resistance in C. elegans”: J. A. Dent, Proc. Natl. Acad. Sci. USA 2000, 97, 2674–2679.
108. “Drug resistance in veterinary helminths”: A. J. Wolstenholme, Trends Parasitol. 2004, 20, 469–476.
109. “Ivermectin resistance in Onchocerca volvulus: Toward a genetic basis”: S. Lustigman, J. P. McCarter, PLoS Neglected Trop. Dis. 2007, 1, e76.
110. “Cloning of the gene encoding avermectin B 5-O-methyltransferase in avermectin-producing Streptomyces avermitilis”: H. Ikeda, L.-R. Wang, T. Ohta, J. Inokoshi, S. Ōmura, Gene 1998, 206, 175–180.
111. “Avermectin biosynthesis”: H. Ikeda, S. Ōmura, Chem. Rev. 1997, 97, 2591–2609.
112. “Organization of the biosynthetic gene cluster for the polyketide anthelmintic macrolide avermectin in Streptomyces avermitilis”: H. Ikeda, T. Nonomiya, M. Usami, T. Ohta, S. Ōmura, Proc. Natl. Acad. Sci. USA 1999, 96, 9509–9514.
113. “Organization of biosynthetic gene cluster for avermectin in Streptomyces avermitilis: analysis of enzymatic domains in four polyketide synthases”: H. Ikeda, T. Nonomiya, S. Ōmura, J. Ind. Microbiol. Biotechnol. 2001, 27, 170–176.
114. “LL-F28249 antibiotic complex: a new family of antiparasitic macrocyclic lactones. Isolation, characterization and structures of LL-F28249 alpha, beta, gamma, lambda”: G. T. Carter, J. A. Nietsche, M. R. Hertz, D. R. Williams, M. M. Siegel, G. O. Morton, J. C. James, D. B. Borders, J. Antibiot. 1988, 41, 519–529.
115. “Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites”: S. Ōmura, H. Ikeda, J. Ishikawa, A. Hanamoto, C. Takahashi, M. Shinose, Y. Takahashi, H. Horikawa, H. Nakazawa, T. Osonoe, H. Kikuchi, T. Shiba, Y. Sakaki, M. Hattori, Proc. Natl. Acad. Sci. USA 2001, 98, 12215–12220.
116. “Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis”: H. Ikeda, J. Ishikawa, A. Hanamoto, M. Shinose, H. Kikuchi, T. Shiba, Y. Sakaki, M. Hattori, S. Ōmura, Nat. Biotechnol. 2003, 21, 526–531.
117. “Genomic basis for natural product biosynthetic diversity in the actinomycetes”: M. Nett, H. Ikeda, B. S. Moore, Nat. Prod. Rep. 2009, 26, 1362–1384.
118. “Genome-minimized Streptomyces host for the heterologous expression of secondary metabolism”: M. Komatsu, T. Uchiyama, S. Ō, D. E. Cane, H. Ikeda, Proc. Natl. Acad. Sci. USA 2010, 107, 2646–2651.
119. “Treatment of human Mansonella streptocerca infection with ivermectin”: P. Fischer, J. Bamuhiiga, D. W. Büttner, Trop. Med. Int. Health 1997, 2, 191–199.
120. “Therapeutic potential of myrrh and ivermectin against experimental Trichinella spiralis infection in mice”: M. M. Basyoni, A. A. El-Sabaa, Korean J. Parasitol. 2013, 51, 297–304.
121. “Oral myiasis treated with ivermectin: case report”: E. H. Shinohara, M. Z. Martini, H. G. de Oliveira Neto, A. Takahashi, Braz. Dent. J. 2004, 15, 79–81.
122. “Avermectins in insect control and biology: a review”: L. Strong, T. A. Brown, Bull. Entomol. Res. 1987, 77, 357–389.
123. “Ivermectin as a systemic insecticide”: H. C. Jackson, Parasitol. Today 1989, 5, 146–156.
124. “Mortality and infertility in adult mosquitoes after the ingestion of blood containing ivermectin”: R. B. Tesh, H. Guzman, Am. J. Trop. Med. Hyg. 1990, 43, 229–233.
125. “Ivermectin causes Cimex lectularius (Bedbug) morbidity and mortality”: J. M. Sheele, J. F. Anderson, T. D. Tran, Y. A. Teng, P. A. Byers, B. S. Ravi, D. E. Sonenshine, J. Emerg. Med. 2013, 45, 433–440.
126. “Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans; the potential of oral insecticides in malaria control”: C. Chaccour, J. Lines, C. J. M. Whitty, J. Infect. Dis. 2010, 202, 113–116.
127. “The effect of oral anthelmintics on the survivorship and re-feeding frequency of anthropophilic mosquito disease vectors”: K. C. Kobylinski, K. M. Deus, M. P. Butters, T. Hongyu, M. Gray, I. M. da Silva, M. Sylla, B. D. Foy, Acta Trop. 2010, 116, 119–126.
128. “Ivermectin mass drug administration for humans disrupts malaria parasite transmission in Senegalese villages”: K. C. Kobylinski, M. Sylla, P. L. Chapman, M. D. Sarr, B. D. Foy, Am. J. Trop. Med. Hyg. 2011, 85, 3–5.
129. “Plasmodium falciparum signal recognition particle components and anti-parasitic effect of ivermectin in blocking nucleo-cytoplasmic shuttling of SRP”: M. Panchal, K. Rawat, G. Kumar, K. M. Kibria, S. Singh, M. Kalamuddin, A. Mohmmed, P. Malhotra, R. Tuteja, Cell Death Dis. 2014, 5, e994.
130. “Endectocides for malaria control”: B. D. Foy, K. C. Kobylinski, I. M. da Silva, J. L. Rasgon, M. Sylla, Trends Parasitol. 2011, 27, 423–428.
131. “Ivermectin as a rodent feed-through insecticide for control of immature sand flies (Diptera: Psychodidae)”: T. M. Mascari, M. A. Mitchell, E. D. Rowton, L. D. Foil, J. Am. Mosq. Control Assoc. 2008, 24, 323–326.
132. “Comparison between the efficacy of ivermectin and other drugs in treatment of cutaneous leishmaniasis”: M. A. Kadir, H. S. Aswad, A. M. Al-Samarai, G. A. Al-Mula, J. Iraqi Vet. Sci. 2009, 23, 175–180.
133. “Effects of ivermectin on blood-feeding Phlebotomus papatasi and the promastigote stage of Leishmania major”: H. A. Hanafi, D. E. Szumlas, D. J. Fryauff, S. S. El-Hossary, G. A. Singer, S. G. Osman, N. Watany, B. D. Furman, D. F. Hoel, Vector Borne Zoonotic Dis. 2011, 11, 43–52.
134. “Efficacy of ivermectin on the infectivity of Leishmania major promastigotes”: K. A. Rasheid, T. A. Morsy, J. Egypt Soc. Parasitol. 1998, 28, 207–212.
135. “Efficacy of systemic administration of ivermectin against tsetse flies”: W. Distelmans, F. D′Haeseleer, J. Mortelmans, Ann. Soc. Belge Med. Trop. 1983, 83, 119–125.
136. “Decrease in survival and fecundity of Glossina palpalis gambiensis vanderplank 1949 (Diptera; Glossinidae) fed on cattle treated with single doses of ivermectin”: S. H. Pooda, K. Mouline, T. De Meeûs, Z. Bengaly, P. Solano, Parasites Vectors 2013, 6, 165.
137. “Effect of ivermectin on Trypanosoma brucei brucei in experimentally infected mice”: U. K. Udensi, A. F. Fagbenro-Beyioku, J. Vector Borne Dis. 2012, 49, 143–150.
138. “Ivermectin is a specific inhibitor of importin a/b-mediated nuclear import able to inhibit replication of HIV-1 and dengue viruses”: K. M. Wagstaff, H. Sivakumaran, S. M. Heaton, D. Harrich, D. A. Jans, Biochem. J. 2012, 443, 851–856.
139. “Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug”: E. Mastrangelo, M. Pezzullo, T. De Burghgraeve, S. Kaptein, B. Pastorino, K. Dallmeier, X. de Lamballerie, J. Neyts, A. M. Hanson, D. N. Frick, M. Bolognesi, M. Milani, J. Antimicrob. Chemother. 2012, 67, 1884–1894.
140. “Nuclear localization of dengue virus (DENV) 1–4 non-structural protein 5: protection against all 4 DENV serotypes by the inhibitor ivermectin”: M. Y. Tay, J. E. Fraser, W. K. Chan, N. J. Moreland, A. P. Rathore, C. Wang, S. G. Vasudevan, D. A. Jans, Antiviral Res. 2013, 99, 301–306.
141. “Ivermectin inhibits growth of Chlamydia trachomatis in epithelial cells”: M. A. Pettengill, V. W. Lam, I. Ollawa, C. Marques-da-Silva, D. M. Ojcius, PLoS ONE 2012, 7, e48456.
142. “Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains”: L. E. Lim, C. Vilchèze, C. Ng, W. R. Jacobs Jr, S. Ramón-García, C. J. Thompson, Antimicrob. Agents Chemother. 2013, 57, 1040–1046.
143. “In-vitro activity of avermectins against Mycobacterium ulcerans”: T. F. Omansen, J. L. Porter, P. D. Johnson, T. S. van der Werf, Y. Stienstra, T. P. Stinear, PLoS Neglected Trop. Dis. 2015, 9, e0003549.
144. 2The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells“: S. Sharmeen, M. Skrtic, M. A. Sukhai, R. Hurren, M. Gronda, X. Wang, S. B. Fonseca, H. Sun, T.E. Wood, R. Ward, M. D. Minden, R. A. Batey, A. Datti, J. Wrana, S. O. Kelley, A. D. Schimmer, Blood 2010, 116, 3593–3603.
145. 2Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs“: M. Shen, Y. Zhang, N. Saba, C. P. Austin, A. Wiestner, D. S. Auld, PLoS ONE 2013, 8, e75252.
146. “Potentiation of doxorubicin-induced apoptosis of resistant mouse leukaemia cells by ivermectin”: S. Furusawa, H. Shibata, H. Nishimura, S. Nemoto, M. Takayanagi, Y. Takayanagi, K.-I. Sasaki, Pharm. Pharmacol. Commun. 2010, 6, 129–134.